Cytokinetics Inc. (CYTK)

Trade CYTK now with
5/11/2023 7:53:47 AM Cytokinetics Begins Phase 1 Clinical Study Of CK-4021586
12/7/2022 7:40:58 AM Cytokinetics Announces Initiation Of Phase 1 Clinical Study Of CK-3828136
6/24/2022 7:35:26 AM Cytokinetics Says FDA Advisory Committee Meeting To Review NDA For Omecamtiv Mecarbil On December 13, 2022
6/17/2022 7:35:13 AM Cytokinetics Provides Regulatory Update For Omecamtiv Mecarbil; Extends PDUFA Date By 3 Months To Feb 28, 2023
4/3/2022 2:00:25 PM Cytokinetics Presents Results From METEORIC-HF And Addl Data From GALACTIC-HF At American College Of Cardiology
2/4/2022 7:48:14 AM Cytokinetics : FDA Accepts NDA Of Omecamtiv Mecarbil For Treatment Of Heart Failure With Reduced Ejection Fraction
2/4/2022 7:34:42 AM Cytokinetics Announces FDA Acceptance For Omecamtiv Mecarbil NDA For Heart Failure With Reduced Ejection Fraction
1/7/2022 7:36:16 AM Cytokinetics Secures Long-term Capital From Royalty Pharma To Support Potential Commercialization Of Omecamtiv Mecarbil
12/20/2021 7:50:07 AM Cytokinetics Says JI XING To Develop Novel Cardiac Myosin Activator In Patients With Heart Failure
6/15/2021 7:37:24 AM Cytokinetics Announces Completion Of Patient Enrollment In METEORIC-HF
5/19/2021 7:39:39 AM Cytokinetics, ALS Association Renew Partnership To Fight Against Amyotrophic Lateral Sclerosis
5/17/2021 8:25:58 AM Cytokinetics Presents Data From Secondary Analysis Of GALACTIC-HF
4/12/2021 7:37:39 AM Cytokinetics Presents Preclinical Data For CK-3773274 At American Chemical Society Spring 2021 Virtual Meeting
2/18/2021 7:44:03 AM Cytokinetics Names Muna Bhanji To Board